ArticleAnti-cancer agents in medicinal chemistry2025

Virtual Screening and Biological Evaluation of T22306 as a Potent Third-generation EGFR Inhibitor for NSCLC Treatment.

Ran Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.